Home
#Global Trends
#Vietnam
#M&A
#Regulations
#Knowledge
Newletter
Events

Home
#Global Trends
#Vietnam
#M&A
#Regulations
#Knowledge
Newletter
Events

Category: Uncategorized

TEVA’S TEV-408 PHASE 2A SUCCESS OPENS A NEW THERAPEUTIC PATHWAY IN CELIAC DISEASE AND STRENGTHENS ITS IMMUNOLOGY PIVOT

03/09/2026 Published by HealthBiz

Key Development Teva Pharmaceutical Industries has reported positive Phase 2a topline results for TEV-408, an investigational human monoclonal antibody targeting... Read more

Tags: #Global Trends

Public Health & Seasonal Immunization: US FDA Clears Pfizer and BioNTech’s Updated COMIRNATY® XFG mRNA Vaccine for the 2026–2027 Respiratory Season Targeting Circulating SARS-CoV-2 Variants

31/08/2026 Published by Pharma Biz

Key Development On August 28, 2026, the U.S. Food and Drug Administration (FDA) officially approved the supplemental Biologics License Application... Read more

Category: Uncategorized

Tags: #Global Trends

Antiviral Therapeutics & Formulation Innovation: US FDA Approves Gilead’s Bixlenvo® (Bictegravir / Lenacapavir) as First and Smallest Once-Daily Single-Tablet Regimen for Virologically Suppressed HIV Adults Transitioning from Multi-Pill Regimens

31/08/2026 Published by Pharma Biz

Key Development On August 28, 2026, the U.S. Food and Drug Administration (FDA) officially granted marketing approval for Bixlenvo® (bictegravir... Read more

Category: Uncategorized

Tags: #Global Trends

Precision Oncology & Next-Gen ADC Platforms: Genentech and DualityBio Enter Potential $1 Billion+ Global Alliance to Pioneer Novel Payload-Linker Platforms Overcoming Topoisomerase Inhibitor Resistance

31/08/2026 Published by Pharma Biz

Key Development On August 28, 2026, clinical-stage biotechnology innovator DualityBio entered into an exclusive global research collaboration and licensing agreement... Read more

Category: Uncategorized

Tags: #M&A

Consumer Healthcare & FMCG Mega-Merger: Kimberly-Clark Requests European Commission Clearance for $40 Billion Acquisition of Kenvue to Form $32 Billion Powerhouse with $2.1 Billion Annual Cost Synergies

31/08/2026 Published by Pharma Biz

Key Development On August 28, 2026, global personal care and consumer products enterprise Kimberly-Clark Corporation (NYSE: KMB) formally submitted a... Read more

Category: Uncategorized

Tags: #M&A

Infectious Disease & Antiviral Innovation: US FDA Approves Gilead’s Bixlenvo® (Bictegravir / Lenacapavir) as Once-Daily Single-Tablet Regimen for Virologically Suppressed HIV-1 Adult Patients on Complex Multi-Pill Regimens

31/08/2026 Published by Pharma Biz

Key Development On August 27, 2026, the U.S. Food and Drug Administration (FDA) approved Bixlenvo® (bictegravir 75 mg / lenacapavir... Read more

Category: Uncategorized

Tags: #Global Trends

Cardiometabolic Therapeutics & Regulatory Label Expansion: US FDA Clears Eli Lilly’s Mounjaro® (Tirzepatide) to Reduce Major Cardiovascular Events in Adults with Type 2 Diabetes – Outperforming Trulicity® by 8%

31/08/2026 Published by Pharma Biz

Key Development On August 28, 2026, the U.S. Food and Drug Administration (FDA) approved an expanded indication for Mounjaro® (tirzepatide),... Read more

Category: Uncategorized

Tags: #Global Trends

Biopharmaceutical CDMO Consolidation: Samsung Biologics Formally Initiates $1.80 Billion Public Takeover Offer for Swiss Peptide Specialist PolyPeptide Group to Solidify Global GLP-1 Supply Dominance

31/08/2026 Published by Pharma Biz

Key Development On August 31, 2026, South Korean biomanufacturing powerhouse Samsung Biologics (KRX: 207940) formally published its public takeover offer... Read more

Category: Uncategorized

Tags: #M&A

Cardiovascular Clinical Trials & RNA Therapeutics: AstraZeneca and Ionis Detail Phase 3 CARDIO-TTRansform Data at ESC Congress, Invalidating the Silencer-Plus-Stabilizer Paradigm in Transthyretin Amyloid Cardiomyopathy (ATTR-CM)

31/08/2026 Published by Pharma Biz

Key Development At the European Society of Cardiology (ESC) Congress 2026 in Munich, AstraZeneca (LSE/STO/Nasdaq: AZN) and Ionis Pharmaceuticals (Nasdaq:... Read more

Category: Uncategorized

Tags: #Global Trends

Posts pagination

Previous page Page 1 … Page 28 Page 29 Page 30 … Page 225 Next page

Facebook

Map

Workday: Monday to Friday
Working hours: 8am to 5pm
Address: 8th floor, Hyco 4 building, 205A Nguyen Xi Street, Binh Thanh Ward, HCMC

Please enable JavaScript in your browser to complete this form.

Email *

Get Your Weekly Market Insights Stay informed on Vietnam's market & Healthcare Alliance updates

Category: Uncategorized

Facebook

Map

Online Members